US points corruption allegations at Novartis

Published On 2015-07-04 07:32 GMT | Update On 2015-07-04 07:32 GMT

Seeks $3.3 billion as fine from the drug manufacturer.

Swiss Drug Maker, Novartis has seemed to rub the US authorities on the wrong side of the duty, with an alleged misrepresentation of facts for medical reimbursements. The authorities have filed a legal complaint against the pharma giant, seeking $3.3 billion as potential damages. What lies beneath is the alleged story of Novartis having coaxed pharmacy chains to convince customers to fill or refill relevant prescriptions with Exjade or Myfortic -- which respectively lowers blood iron levels and combats the risk of rejection in kidney transplant patients -- in exchange for rebates and other advantages.

The allegation of using kick backs to boost the drug sales is further substantiated by the fact of 126,802 prescriptions for Novartis medication Exjade, and 39,209 for Myfortic submitted by pharmacies for a total $508 million in reimbursements from government health care programs.

Stating that this unruly arrangement cost millions of exchequer loss to the US health programmes, US justice officials are seeking a compensation amounting to $11,000 per prescription, three times the amount paid out.

Novartis, has in the meanwhile maintained a clear stand that it only offered legal rebates to pharmacies it worked with.

The filing notes that Novartis maintains it offered legal rebates to pharmacies it worked with.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

US points corruption allegations at Novartis

Similar News

MoS Health urges youth to lead tobacco-free, addiction-free movement

Lyme disease confirmed in Himachal Pradesh; 17 test positive

Swasth Nari Sashakt Parivar Abhiyaan concludes, benefits over 6.5 crore women

Jharkhand HC directs Govt to frame HIV guidelines for prison inmates

Bhopal Gas Tragedy: SC issues contempt notices to Health Ministry, ICMR over non-compliance of orders on medical care

Chhattisgarh NHM employees end strike after Government Talks

India conferred with Bloomberg Philanthropies Global Tobacco Control Award

LIC eyes entry into health insurance space by month end